Amgen (AMGN) Gets a Buy from Piper Sandler
Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...
Amgen, Kyowa announces new results from ongoing ROCKET Phase 3 study
Amgen (AMGN) and Kyowa Kirin (KYKOF) announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an ...
Drugmaker Amgen to Invest $200 Million in India Site, CEO Says
HYDERABAD, India (Reuters) - U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, CEO Robert Bradway said at ...